

July 10, 2026

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
---	---

Dear Sir / Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is to inform you that PT Aurogen Pharma Indonesia, a wholly owned stepdown subsidiary of the Company, has incorporated a new wholly owned subsidiary company by the name of PT Auro Pharm Indonesia, in Indonesia.

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as '**Annexure A**'.

This is for your information and records.

Yours faithfully,

For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

Enclosures: Annexure A

(CIN : L24239TG1986PLC015190)

AUROBINDO PHARMA LIMITED

www.aurobindo.com

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd.off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad -500038 Telangana., India Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

Annexure -A
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

a) Name of the target entity, details in brief such as size, turnover etc.;	Name: PT Auro Pharm Indonesia, Indonesia Turnover: Not applicable as the company was incorporated on July 1, 2026 and the approval from the authorities for incorporation was received on July 9, 2026.
b) Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group / group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms-length";	PT Auro Pharm Indonesia, Indonesia, is incorporated as a wholly owned step-down subsidiary of the Company and therefore is a related party of the Company. Promoters and promoter group of the Company are not interested in the transaction
c) Industry to which the business of the target entity being acquired belongs;	Pharmaceuticals
d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The object of incorporation of this wholly owned step-down subsidiary is to undertake manufacturing operations in Indonesia.
e) Brief details of any governmental or regulatory approvals required for the acquisition.	No governmental or regulatory approvals required.
f) Indicative time period for completion of the acquisition.	Not applicable
g) Nature of consideration - whether cash consideration or share swap or any other form and details of the same;	100% subscription to the share capital in cash
h) Cost of acquisition and / or the price at which the shares are acquired; New Subsidiary was incorporated.	Initial subscription to the share capital of IDR 20,000,000,000 divided into 2000 equity shares of IDR, 10,000,000 each.
i) Percentage of shareholding / control acquired and or number of shares acquired;	100%
j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	This is a newly incorporated company and therefore the history of the last 3 years' turnover is not available. PT Auro Pharm Indonesia was incorporated on July 1 st 2026 in Indonesia and the approval from the authorities for incorporation was received on July 9, 2026.

AUROBINDO PHARMA LIMITED
www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad -500038 Telangana., India Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com